{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T19:46:39Z","timestamp":1788291999965,"version":"build-2803163510"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.bcp.2020.114042","type":"journal-article","created":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T02:40:10Z","timestamp":1590028810000},"page":"114042","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Flurbiprofen as a biphenyl scaffold for the design of small molecules binding to PD-L1 protein dimer"],"prefix":"10.1016","volume":"178","author":[{"given":"Christian","family":"Bailly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard","family":"Vergoten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2020.114042_b0005","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.pharmthera.2018.09.008","article-title":"Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): a new era in cancer active immunotherapy","volume":"194","author":"Constantinidou","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2020.114042_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/narcan\/zcaa002","article-title":"Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times","volume":"2","author":"Bailly","year":"2020","journal-title":"NAR Cancer"},{"key":"10.1016\/j.bcp.2020.114042_b0015","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2217\/imt-2018-0110","article-title":"Programmed cell death-1\/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action","volume":"11","author":"Zhang","year":"2019","journal-title":"Immunotherapy"},{"key":"10.1016\/j.bcp.2020.114042_b0020","doi-asserted-by":"crossref","first-page":"E1190","DOI":"10.3390\/molecules24061190","article-title":"Molecular interactions of antibody drugs targeting PD-1, PD-L1, and CTLA-4 in immuno-oncology","volume":"24","author":"Lee","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.bcp.2020.114042_b0025","doi-asserted-by":"crossref","first-page":"4911","DOI":"10.2174\/1381612824666181112114958","article-title":"Small molecules as PD-1\/PD-L1 pathway modulators for cancer immunotherapy","volume":"24","author":"Jiao","year":"2018","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bcp.2020.114042_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111876","article-title":"Progress in PD-1\/PD-L1 pathway inhibitors: from biomacromolecules to small molecules","volume":"186","author":"Lin","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2020.114042_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113821","article-title":"Protein homodimer sequestration with small molecules: Focus on PD-L1","volume":"174","author":"Bailly","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114042_b0040","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1080\/13543776.2018.1512706","article-title":"A patent review on PD-1\/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015\u20132018)","volume":"28","author":"Shaabani","year":"2018","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bcp.2020.114042_b0045","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.bmcl.2019.01.028","article-title":"Fragment-based screening of programmed death ligand 1 (PD-L1)","volume":"29","author":"Perry","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2020.114042_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111856","article-title":"Discovery of the programmed cell death-1\/programmed cell death-ligand 1 interaction inhibitors bearing an indoline scaffold","volume":"186","author":"Qin","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2020.114042_b0055","doi-asserted-by":"crossref","first-page":"72167","DOI":"10.18632\/oncotarget.20050","article-title":"Small-molecule inhibitors of PD-1\/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells","volume":"8","author":"Skalniak","year":"2017","journal-title":"Oncotarget."},{"key":"10.1016\/j.bcp.2020.114042_b0060","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1016\/j.str.2015.09.010","article-title":"Structure of the complex of human programmed death 1, PD-1, and its ligand PD-L1","volume":"23","author":"Zak","year":"2015","journal-title":"Structure"},{"key":"10.1016\/j.bcp.2020.114042_b0065","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.str.2017.06.011","article-title":"Structural biology of the immune checkpoint receptor PD-1 and its ligands PD-L1\/PD-L2","volume":"25","author":"Zak","year":"2017","journal-title":"Structure"},{"key":"10.1016\/j.bcp.2020.114042_b0070","doi-asserted-by":"crossref","first-page":"E4654","DOI":"10.3390\/ijms20184654","article-title":"Molecular modeling studies on the binding mode of the PD-1\/PD-L1 complex inhibitors","volume":"20","author":"Almahmoud","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2020.114042_b0075","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1039\/C9MD00326F","article-title":"Structural insights and binding analysis for determining the molecular bases for programmed cell death protein ligand-1 inhibition","volume":"10","author":"Ac\u00farcio","year":"2019","journal-title":"Medchemcomm."},{"key":"10.1016\/j.bcp.2020.114042_b0080","doi-asserted-by":"crossref","DOI":"10.1002\/smll.201903881","article-title":"Immune checkpoint blockade mediated by a small-molecule nanoinhibitor targeting the PD-1\/PD-L1 pathway synergizes with photodynamic therapy to elicit antitumor immunity and antimetastatic effects on breast cancer","volume":"15","author":"Zhang","year":"2019","journal-title":"Small"},{"key":"10.1016\/j.bcp.2020.114042_b0085","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2220\/biomedres.40.243","article-title":"Antitumor activity of the PD-1\/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse","volume":"40","author":"Ashizawa","year":"2019","journal-title":"Biomed. Res."},{"key":"10.1016\/j.bcp.2020.114042_b0090","doi-asserted-by":"crossref","first-page":"12392","DOI":"10.1038\/s41598-019-48826-6","article-title":"Comprehensive in vitro characterization of PD-L1 small molecule inhibitors","volume":"9","author":"Ganesan","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2020.114042_b0095","doi-asserted-by":"crossref","first-page":"7250","DOI":"10.1021\/acs.jmedchem.9b00795","article-title":"Design, synthesis, evaluation, and structural studies of C2-symmetric small molecule inhibitors of programmed cell death-1\/programmed death-ligand 1 protein-protein interaction","volume":"62","author":"Basu","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2020.114042_b0100","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.1021\/acs.jmedchem.9b00312","article-title":"Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent inhibitors targeting the programmed cell death-1\/programmed cell death-ligand 1 interaction","volume":"62","author":"Qin","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2020.114042_b0105","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3389\/fchem.2019.00764","article-title":"computational insight into the small molecule intervening PD-L1 dimerization and the potential structure-activity relationship","volume":"7","author":"Shi","year":"2019","journal-title":"Front. Chem."},{"key":"10.1016\/j.bcp.2020.114042_b0110","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jmgm.2019.06.001","article-title":"Pharmacophore model of immunocheckpoint protein PD-L1 by cosolvent molecular dynamics simulations","volume":"91","author":"Mej\u00edas","year":"2019","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.bcp.2020.114042_b0115","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.3389\/fimmu.2019.02298","article-title":"The diverse function of PD-1\/PD-L pathway beyond cancer","volume":"10","author":"Qin","year":"2019","journal-title":"Front Immunol."},{"key":"10.1016\/j.bcp.2020.114042_b0120","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nchembio.663","article-title":"(R)-Profens are substrate-selective inhibitors of endocannabinoid oxygenation by COX-2","volume":"7","author":"Duggan","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bcp.2020.114042_b0125","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1474-4422(08)70090-5","article-title":"Tarenflurbil Phase II Study investigators. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial","volume":"7","author":"Wilcock","year":"2008","journal-title":"Lancet. Neurol."},{"key":"10.1016\/j.bcp.2020.114042_b0130","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.2174\/156802611795860942","article-title":"\u03b3-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes","volume":"11","author":"Imbimbo","year":"2011","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.bcp.2020.114042_b0135","first-page":"5","article-title":"Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer","volume":"8","author":"L\u00f6nnroth","year":"2008","journal-title":"Cancer Immun."},{"key":"10.1016\/j.bcp.2020.114042_b0140","first-page":"354","article-title":"Preoperative intravenous flurbiprofen reduces postoperative pain and inflammatory cytokines in elderly patients after hip arthroplasty","volume":"17","author":"Zhou","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.bcp.2020.114042_b0145","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.ccell.2016.10.010","article-title":"Deubiquitination and Stabilization of PD-L1 by CSN5","volume":"30","author":"Lim","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2020.114042_b0150","doi-asserted-by":"crossref","first-page":"18705","DOI":"10.18632\/oncotarget.7669","article-title":"A short-term increase of the postoperative naturally circulating dendritic cells subsets in flurbiprofen-treated patients with esophageal carcinoma undergoing thoracic surgery","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2020.114042_b0155","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1159\/000503166","article-title":"Intraoperative flurbiprofen treatment alters immune checkpoint expression in patients undergoing elective thoracoscopic resection of lung cancer","volume":"29","author":"Hu","year":"2020","journal-title":"Med. Princ. Pract."},{"key":"10.1016\/j.bcp.2020.114042_b0160","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.cell.2015.08.015","article-title":"Cyclooxygenase-dependent tumor growth through evasion of immunity","volume":"162","author":"Zelenay","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2020.114042_b0165","first-page":"2203","article-title":"E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse","volume":"60","author":"Wechter","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2020.114042_b0170","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.bcp.2006.07.028","article-title":"Gene expression profiling in R-flurbiprofen-treated prostate cancer: R-Flurbiprofen regulates prostate stem cell antigen through activation of AKT kinase","volume":"72","author":"Zemskova","year":"2006","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114042_b0175","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.15252\/emmm.201404168","article-title":"R-flurbiprofen attenuates experimental autoimmune encephalomyelitis in mice","volume":"6","author":"Schmitz","year":"2014","journal-title":"EMBO Mol. Med."},{"issue":"2003","key":"10.1016\/j.bcp.2020.114042_b0180","first-page":"677","article-title":"Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J. Exp. Med. 198 71\u201378 Erratum","volume":"198","author":"Salama","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bcp.2020.114042_b0185","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1021\/acs.jmedchem.7b00293","article-title":"Small-molecule inhibitors of the programmed cell death-1\/programmed death-ligand 1 (PD-1\/PD-L1) interaction via transiently induced protein states and dimerization of PD-L1","volume":"60","author":"Guzik","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2020.114042_b0190","doi-asserted-by":"crossref","first-page":"30323","DOI":"10.18632\/oncotarget.8730","article-title":"Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)","volume":"7","author":"Zak","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2020.114042_b0195","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/0006-2952(95)00048-5","article-title":"Role of cytochrome P450 2C9 and an allelic variant in the 4'-hydroxylation of (R)- and (S)-flurbiprofen","volume":"49","author":"Tracy","year":"1995","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114042_b0200","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jsb.2019.08.011","article-title":"Structure-activity relationships of flurbiprofen analogues as stabilizers of the amyloidogenic protein transthyretin","volume":"208","author":"Loconte","year":"2019","journal-title":"J. Struct. Biol."},{"key":"10.1016\/j.bcp.2020.114042_b0205","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1080\/13506129.2017.1308348","article-title":"CSP-1103 (CHF5074) stabilizes human transthyretin in healthy human subjects","volume":"24","author":"Qiang","year":"2017","journal-title":"Amyloid"},{"key":"10.1016\/j.bcp.2020.114042_b0210","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0014-2999(96)00640-1","article-title":"Effects of flurbiprofen and flurbinitroxybutylester on prostaglandin endoperoxide synthases","volume":"316","author":"Santini","year":"1996","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114042_b0215","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejphar.2008.11.023","article-title":"The nitrosylated flurbiprofen derivative HCT1026 inhibits cytokine-induced signalling through a novel mechanism of action","volume":"602","author":"Idris","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114042_b0220","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1742-2094-7-83","article-title":"Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease","volume":"7","author":"L'Episcopo","year":"2010","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.bcp.2020.114042_b0225","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.bone.2004.03.036","article-title":"van't Hof RJ. The flurbiprofen derivatives HCT1026 and HCT1027 inhibit bone resorption by a mechanism independent of COX inhibition and nitric oxide production","volume":"35","author":"Idris","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.bcp.2020.114042_b0230","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/jcc.20297","article-title":"Molecular modeling of organic and biomolecular systems using BOSS and MCPRO","volume":"26","author":"Jorgensen","year":"2005","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bcp.2020.114042_b0235","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0300-9084(03)00052-X","article-title":"The SPASIBA force field as an essential tool for studying the structure and dynamics of saccharides","volume":"85","author":"Vergoten","year":"2003","journal-title":"Biochimie"},{"key":"10.1016\/j.bcp.2020.114042_b0240","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1021\/jp031178l","article-title":"Increasing normal modes analysis accuracy: The SPASIBA spectroscopic force field introduced into the CHARMM program","volume":"108","author":"Lagant","year":"2004","journal-title":"J. Phys. Chem. A"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295220302768?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295220302768?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:12:45Z","timestamp":1757769165000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295220302768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":48,"alternative-id":["S0006295220302768"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2020.114042","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Flurbiprofen as a biphenyl scaffold for the design of small molecules binding to PD-L1 protein dimer","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2020.114042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114042"}}